Berlin, Germany-based Jerini AG has received notification from the US Food and Drug Administration of its decision to cancel the Pulmonary-Allergy Drugs Advisory Committee meeting scheduled for February 20.
The meeting was originally planned to provide a forum for FDA advisors to discuss the data included in Jerini's New Drug Application for icatibant in the treatment of hereditary angioedema, a disease for which there is currently no approved treatment in the USA. The agency has told the company that an advisory committee meeting is no longer necessary, and that it will continue its priority review of the NDA.
"The results of our Phase III studies demonstrate icatibant's safety and efficacy in treating HAE. We look forward to the FDA's decision and to our receipt of the agency's action letter, which is expected on April 26, 2008," said Jens Schneider-Mergener, chief executive of Jerini.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze